General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Access to healthcare

Novartis collaborates with others to help address some of the world’s greatest health challenges. To help do that, our corporate responsibility programs help more people secure the healthcare they need, regardless of where they live. We’ve done this for a long time, largely through philanthropic and not-for-profit programs. Because the number of people in need continues to exceed the capacity of corporate philanthropy, Novartis and other companies are turning to new ways of reaching people in need, by creating Social Ventures – shared value business models that complement philanthropic and zero-profit initiatives.

We concentrate our efforts on controlling and eliminating diseases such as malaria and leprosy, pioneering new business approaches to reach underserved patients, and finding new treatments and adaptive solutions to improve health for people around the world. In 2013, these efforts reached more than 100 million patients.

Malaria

Every second, Novartis delivers three malaria treatments. Over the past decade, the Novartis Malaria Initiative has become one of the healthcare industry’s largest access-to-medicine programs, delivering more than 600 million antimalarial treatments without profit, including 200 million pediatric treatments. Novartis is expanding its commitment by joining charity Malaria No More’s Power of One campaign and donating medicines to treat up to 3 million children with malaria through 2015. This donation will match the treatments purchased by the public, doubling their impact.

Leprosy

All leprosy patients in the world can receive free treatment from Novartis. We’ve extended our collaboration with the World Health Organization (WHO) to help end leprosy, an ancient disease that carries an intense social stigma. More than 5 million leprosy patients have received free treatment from Novartis through the WHO since 2000.

Novartis will continue to provide free medicines through 2020. To complement this donation and further curb the incidence of leprosy, the Novartis Foundation for Sustainable Development (NFSD) announced a new strategy to achieve zero transmission of the disease.

Tuberculosis

Every four seconds, someone is infected with tuberculosis. Yet, despite the loss of millions of lives, it remains one of the most neglected diseases by pharmaceutical companies due to its lack of commercial potential. Sandoz, the division of Novartis that makes generic medicines, has a long history of fighting TB and is the main provider of TB drugs to the World Health Organization.

Noncommunicable diseases

While infectious diseases remain the biggest killers in developing countries, the pattern of disease is changing. For example, sub-Saharan Africa increasingly faces a ‘double burden’ of disease with a rising prevalence of noncommunicable diseases. Data indicate that people in Africa have the world’s highest incidence of elevated blood pressure and the number of strokes is expected to reach epidemic levels in coming years.

While many treatments already exist for these conditions, it’s hard to find clear data on how big the problem is. That’s due to many factors, including the reality that access to healthcare is restricted for millions of people in Africa due to a lack of physical infrastructure, such as transportation systems, and a lack of capacity within the healthcare system. For example, Africa has two physicians and nine hospital beds per 10 000 people. By contrast, Europe has 33 physicians and 62 beds for every 10 000 people.

To help get medicines to cancer patients in the developing world, we established the first global direct-to-patient access program. The Glivec International Patient Assistance program helps patients receive treatment for two rare cancers. The program has become one of the world’s most far-reaching patient assistance programs, active in more than 80 low- to middle-income countries. Our partner, The Max Foundation, also provides patients with emotional support in addition to medicines. The Novartis Oncology Access program provides assistance to patients with other cancers.

Social Ventures

Social ventures build local, sustainable capabilities for healthcare around the world. These programs address societal problems that impact access to healthcare, including the need for education, infrastructure and healthcare distribution. Novartis has social ventures projects in India, Kenya, Vietnam, China and Zambia.